论文信息 - Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma - 字舞流文

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

N. Pavlakis | K. O'Byrne | B. Thapa | P. Russell | S. Kao | T. John | B. Hughes | S. Rothschild | A. Nowak | D. Klingbiel | U. Petrausch | O. Gautschi | M. Pless | R. V. Von Moos | P. Froesch | S. Savic | W. Mingrone | M. Früh | Y. Metaxas | G. Rivalland | S. Schmid | H. Bouchaab | L. Mauti | T. Bartnick | Sibylle Wolleb | Melanie Löffler-Baumann | Susanne Pratsch-Peter | R. von Moos | M. Löffler‐Baumann

[1] T. Seiwert,et al. Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). , 2018 .

[2] J. Taube,et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[3] A. Santoro,et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.

[4] F. Hirsch,et al. PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[6] Manish R. Patel,et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression. , 2016 .

[7] Jedd D. Wolchok,et al. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[8] Thomas D. Wu,et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[9] J. V. van Meerbeeck,et al. Second line therapy in malignant pleural mesothelioma: A systematic review. , 2015, Lung cancer.

[10] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[11] A. Mansfield,et al. Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. , 2014, Lung cancer.

[12] C. Sima,et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. , 2014, Lung cancer.

[13] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.